Form 4: Sutro Biopharma Director Michael Dybbs Granted 50,000 Stock Options

Sutro Biopharma, Inc. Director Michael Dybbs was granted 50,000 stock options with an exercise price of $0.85, vesting monthly and fully by June 2026.

Summary

• Michael Dybbs, a Director of Sutro Biopharma, Inc. (STRO), was granted 50,000 stock options.
• The options have an exercise price of $0.85 per share.
• The grant date for these options was June 6, 2025.
• The options will vest at a rate of 8.33% of the total shares monthly, commencing July 6, 2025.
• Full vesting (100%) will occur on the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026.
• The vesting is contingent upon Mr. Dybbs' continued provision of service to the issuer on each vesting date.
• The options expire on June 6, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management's interests with shareholders. It's a routine compensation event, not indicative of major operational changes, hence a moderately positive score reflecting standard corporate governance practices.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The exercise price of $0.85 is relatively low, offering potential for significant upside if the company's stock price appreciates.

Risks

• The ultimate value of the stock options is contingent on Sutro Biopharma's stock price exceeding the exercise price of $0.85 in the future.
• The vesting of the options is subject to the reporting person's continued service to the issuer, meaning the full benefit is not guaranteed if service ceases prematurely.

Future Outlook

This filing indicates a standard equity compensation grant to an existing director, aligning their future incentives with the company's long-term performance. The vesting schedule extends through mid-2026, suggesting a continued commitment from the director to the company's strategic objectives.

Industry Context

The grant of stock options is a common and widely accepted practice in the biopharmaceutical industry to attract, retain, and incentivize key talent, including board members. This mechanism aligns the financial interests of directors with the long-term success of the company and shareholder value creation, which is particularly relevant in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• Granting stock options to directors is a standard component of executive and board compensation packages across publicly traded companies, especially within growth-oriented sectors like biopharma.
• The specific number of options (50,000) and the exercise price ($0.85) would typically be evaluated against compensation benchmarks for directors at companies of comparable market capitalization, stage of development, and industry focus within the biopharma sector. Without specific comparable data from similar companies (e.g., other clinical-stage biotechs with similar market caps), a detailed assessment of whether this grant is above, below, or in line with industry averages is not possible, but the compensation mechanism itself is standard.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders through incentivized long-term value creation. Future exercise of options could lead to minor dilution.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Michael Dybbs is expected to continue providing service to Sutro Biopharma, Inc. to fulfill the vesting conditions of the options.
• The stock options will continue to vest monthly, with full vesting by June 6, 2026, or the 2026 annual stockholders meeting, whichever is earlier.
• The options can be exercised at $0.85 per share until their expiration date of June 6, 2035.

Key Dates

Recommendation

Keywords

Sutro Biopharma, STRO, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biopharma